Article and Video CATEGORIES
Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.
Please feel free to offer comments and raise questions in our Discussion Forums.
Dr. West: Turning to the issues of what’s emerging in mesothelioma, it seems that there’s a lot of interest in immunotherapies in this setting. Any sense of early data in that, how hopeful you are?
Dr. Solomon: So, it was with pembrolizumab, and again, a small study, and a response rate of about 29%, and I think that’s encouraging, and I think this is in patients who had prior platinum pemetrexed, and this is a setting where there isn’t a standard second-line treatment, so I think that sort of response rate, again, is a meaningful response rate, and there are a number of other studies that are going with the other different PD-1 or PD-L1 inhibitors, alone or in combination with CTLA-4 inhibitors.
Dr. Horn: The pembrolizumab study, from what I remember, was only in PD-L1-positive patients.
Dr. Solomon: I think that’s right, and we may talk about PD-L1 as a biomarker later, but I think an interesting observation was that the didn’t find that the degree of PD-L1 scoring correlated with the likelihood of response, in mesothelioma.
Please feel free to offer comments and raise questions in our
Next Previous linkPrevious PostNext Post
Hi Caregiver and welcome to Grace. I'm sorry that you need to be here and hope we can help. Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...
Hi Bob, Welcome to Grace. I'm sorry about your sil. Unfortunately, cancer becomes resistant to TKIs like tagrisso. Sometimes all of the cancer becomes resistant at once and sometimes just parts...